Clinical Outcomes of Placenta Previa - an Individualized Scoring System

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-01-04

Study Completion Date

2026-05-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the study is to develop a machine learning -based prediction model for patients with placenta previa . The model will be based on patient characteristics, clinical assessment, and disease features to predict disease course, prognosis and establish an individualized plan of care. Individualized management plan comprises timing of delivery, mode of delivery, need for hospital admission, postpartum hemorrhage management plan, and perioperative care.

The primary outcome is to predict maternal complications, primarily major antepartum hemorrhage (APH), defined as blood loss of 50-1000 ml.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prediction of Placenta Accreta Outcome in Pregnant Woman With Placenta Previa Using (hcg_h ) as Abiomarkers

NCT06761885

Placenta Accreta / Percreta

NOT_YET_RECRUITING

Characteristics, Complications and Perinatal Outcomes in Placenta Previa Women

NCT03774667

Placenta Previa

UNKNOWN

The Placenta Previa and Fetal Weight

NCT03321435

Placenta Previa

COMPLETED

Placental Risk Assessment to CusTomize Individualized Pregnancy Care and Evaluation

NCT07144839

Stillbirth Placental Insufficiency

RECRUITING

Anxiety and Depressive Symptoms in Placenta Previa / Accreta

NCT05529381

Anxiety Depression Placenta Previa

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

• Study settings: This multi-center study will invite at least 8 European-based tertiary centers. Data will be retrospectively collected from January 2018 to December 2023. with a total follow-up of at least 6 weeks postpartum. All women who will be diagnosed with PP during this period will be considered in the study.

• Inclusion Criteria:

* Pregnant women diagnosed with placenta previa at time of routine second trimester ultrasound (18 to 21 weeks of gestation).
* Aged 18 years old or above.
* Diagnosed with PP, followed-up antenatally and delivered within the same center.
* Authorization to use anonymous patient data for research purposes.

Exclusion Criteria:

* Inadequate documentation.
* Non-compliance to antenatal care.
* Previous 1 or more Cesarean deliveries.
* Previous uterine surgeries that approach the uterine cavity (myomectomy).
* Known untreated uterine septum.
* Maternal chronic medical condition that is associated with higher risk of placental insufficiency (including chronic hypertension, pregestational diabetes, chronic renal disease, autoimmune disease).
* Fetal major congenital anomalies.

Data Collection A standardized data collection spreadsheet is designed for this study and will be available for all participating centers. The sheet will comprise drop lists for all nominal, ordinal and binary variables to ensure consistency. Target data will include patient demographics (age, parity, gestational age at diagnosis, mode of conception, body mass index at booking and at delivery, pregnancy interval), hemoglobin at booking, past medical and surgical history, and the presence of any current complications in pregnancy. Diagnostic information including placental location, distance from internal os, the presence of other placental abnormalities as well as diagnostic modality will be collected. Follow-up from the 32-week scan and any subsequent scans will be explored and further follow-up information including hemoglobin levels, bleeding episodes, need for transfusion, administration of steroids, fetal growth, and maternal and neonatal outcomes, will be reviewed, and collected.

Data sheets will be sent on completion to the primary investigators to review and inquire on any unclear entry prior to data cleaning and data analysis.

Secondary outcomes include prediction of need for antenatal transfusion, emergency cesarean delivery, and massive postpartum hemorrhage (defined as blood loss \&gt; 2000 ml), and neonatal admission to neonatal intensive care unit (NICU).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Placenta Previa

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Pregnant women diagnosed with placenta previa at time of routine second trimester ultrasound (18 to 21 weeks of gestation).

Aged 18 years old or above. Diagnosed with PP, followed-up antenatally and delivered within the same center.

Authorization to use anonymous patient data for research purposes

Exclusion Criteria

Inadequate documentation. Non-compliance to antenatal care. Previous 1 or more Cesarean deliveries. Previous uterine surgeries that approach the uterine cavity (myomectomy). Known untreated uterine septum. Maternal chronic medical condition that is associated with higher risk of placental insufficiency (including chronic hypertension, pregestational diabetes, chronic renal disease, autoimmune disease).

Fetal major congenital anomalies

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No